SCHEDULE 13G 0001425851 XXXXXXXX LIVE Ordinary Shares, nominal value 0.05 GBP per share 09/30/2025 0001657312 Verona Pharma plc 925050106 3 MORE LONDON RIVERSIDE LONDON X0 SE1 2RE Rule 13d-1(b) Pentwater Capital Management LP DE 0.00 0.00 0.00 0.00 0.00 N 0 IA PN The information set forth on this cover page reflects information as of the date hereof. As of September 30, 2025, the Reporting Persons may have been deemed to beneficially own 42,400,000 Ordinary Shares (as defined in Item 2(a)) represented by 5,300,000 ADSs (as defined in Item 2(a)), representing 6.1% of the outstanding Ordinary Shares as of such time. Matthew Halbower X1 0.00 0.00 0.00 0.00 0.00 N 0 HC IN The information set forth on this cover page reflects information as of the date hereof. As of September 30, 2025, the Reporting Persons may have been deemed to beneficially own 42,400,000 Ordinary Shares represented by 5,300,000 ADSs, representing 6.1% of the outstanding Ordinary Shares as of such time. Verona Pharma plc 3 More London Riverside, London SE1 2RE, United Kingdom This statement is filed by: (i) Pentwater Capital Management LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to certain funds (the "Pentwater Funds"), with respect to the ordinary shares, nominal value 0.05 GBP per share ("Ordinary Shares"), of Verona Pharma plc, a public limited company incorporated under the laws of England and Wales (the "Company"), represented by American Depositary Shares ("ADSs") by the Pentwater Funds; and (ii) Mr. Matthew Halbower ("Mr. Halbower"), the sole shareholder of MCH PWCM Holdings Inc., the general partner of the Investment Manager, with respect to the Ordinary Shares, represented by ADSs, held by the Pentwater Funds. There is no CUSIP number assigned to the Ordinary Shares. The CUSIP number 925050106 has been assigned to the ADSs of the Company, which are quoted on the Nasdaq Global Market under the symbol "VRNA." Each ADS represents eight Ordinary Shares. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities and Exchange Act of 1934, the beneficial owner of the securities reported herein. The address of the business office of each of the Reporting Persons is 1001 10th Avenue South, Suite 216, Naples, FL 34102. The Investment Manager is a Delaware limited partnership. Mr. Halbower is a citizen of the United States. N IA HC The information required by Item 4(a) is set forth in Row 9 and the comment box of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentage set forth in this Schedule 13G as of September 30, 2025 is calculated based upon an aggregate of 691,966,902 Ordinary Shares outstanding as of August 11, 2025, as reported in the Company's Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on August 18, 2025. 0% The information required by Item 4(c)(i) is set forth in Row 5 and the comment box of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 and the comment box of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 and the comment box of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 and the comment box of the cover page for each of the Reporting Persons and is incorporated herein by reference. N Y N As of the date hereof, not applicable. As of September 30, 2025, see Item 2(a); the Pentwater Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares reported herein. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1: Joint Filing Agreement Pentwater Capital Management LP /s/ Matthew Halbower 11/14/2025 Matthew Halbower /s/ Matthew Halbower 11/14/2025